CITED4: A Potential Drug Target and Biomarker (G163732)

Target Name: CITED4

NCBI ID: G163732

CITED4

CITED4: A Potential Drug Target and Biomarker

Cimated four (CITE) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. The gene is located on chromosome 12 and encodes a protein known as CITD4.

CITD4 is a transmembrane protein that plays a crucial role in the regulation of intracellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues, and is a target for many diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

Studies have shown that changes in the expression of CITD4 can contribute to the development and progression of these diseases. For example, studies have found that CITD4 levels are often elevated in various types of cancer, and that inhibiting CITD4 can lead to therapeutic benefits in these diseases.

In addition to its potential as a drug target, CITD4 has also been identified as a potential biomarker for several diseases. For example, studies have shown that CITD4 levels can be used as a diagnostic marker for neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target and biomarker, CITD4 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. This includes the regulation of cell adhesion, migration, and the formation of tissues and organs.

Given the importance of CITD4 in the regulation of cellular processes, it is a promising target for drug development. Researchers are currently working to identify small molecules that can specifically modulate CITD4 function and determine their potential therapeutic benefits.

In conclusion, CITD4 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Further research is needed to fully understand its function and develop effective therapies based on its modulation.

Protein Name: Cbp/p300 Interacting Transactivator With Glu/Asp Rich Carboxy-terminal Domain 4

Functions: Acts as transcriptional coactivator for TFAP2/AP-2. Enhances estrogen-dependent transactivation mediated by estrogen receptors. May function as an inhibitor of transactivation by HIF1A by disrupting HIF1A interaction with CREBBP. May be involved in regulation of gene expression during development and differentiation of blood cells, endothelial cells and mammary epithelial cells

The "CITED4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CITED4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets